Difference between revisions of "T-cell prolymphocytic leukemia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(added some regimens, reference. please confirm that early clinical reports/abstracts are ok (ven/ibrutinib regimen))
Tag: visualeditor
m
Line 18: Line 18:
 
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas]
 
*[https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf NCCN Guidelines - T-cell Lymphomas]
  
−
==Diagnosis, staging and treatment response criteria (TPLL-ISG)==
+
=Diagnosis, staging and treatment response criteria (TPLL-ISG)=
  
 
*'''2019:''' Staber et al. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000402 Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia]
 
*'''2019:''' Staber et al. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000402 Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia]
Line 29: Line 29:
 
|}
 
|}
 
===Regimen {{#subobject:893a|Variant=1}}===
 
===Regimen {{#subobject:893a|Variant=1}}===
−
{| class="wikitable" style="width: 50%; text-align:center;"  
+
{| class="wikitable" style="width: 75%; text-align:center;"  
−
! style="width: 25%" |Study
+
!style="width: 33%"|Study
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
!Efficacy
+
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
 
|[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 Dearden et al. 2001]
 
|[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 Dearden et al. 2001]
Line 45: Line 45:
 
====Chemotherapy====
 
====Chemotherapy====
  
−
* [[Alemtuzumab (Campath)]]
+
* [[Alemtuzumab (Campath)]] as follows:
 +
**First week: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
 +
**Subsequent weeks: 30 mg IV three times weekly
  
−
First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
+
'''Continued until achievement of CR or best response or for up to a total of 3 months'''
  
−
<big>'''<u>Alemtuzumab, Pentostatin</u>'''</big>
+
===References===
  
−
'''Regimen'''
+
#Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11535503 PubMed]
 +
#Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21948296 PubMed]
 +
 
 +
==Pentostatin & Alemtuzumab {{#subobject:aacb018|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:881cj3a|Variant=1}}===
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
−
! style="width: 25%" |Study
+
!style="width: 33%"|Study
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
!Efficacy
+
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
−
![https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 '''Ravandi et al. 2009''']
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ Ravandi et al. 2009 (MDACC 2004-0408)]
−
!'''Non-randomized'''
+
| style="background-color:#91cf61" |Non-randomized
−
!ORR: 69%, CR: 62%
+
|ORR: 69%, CR: 62%
−
|}<br />
+
|}
 
====Chemotherapy====
 
====Chemotherapy====
  
−
*[[Alemtuzumab (Campath)]] First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
+
*[[Alemtuzumab (Campath)]] as follows:
−
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV weekly for 4 weeks then every 2 weeks until they achieved a CR or best response or for up to 10 more doses (total of 14 doses)
+
**First week: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
 +
**Subsequent weeks: 30 mg IV three times weekly  
 +
*[[Pentostatin (Nipent)]] as follows:
 +
**Weeks 1 to 4: 4 mg/m<sup>2</sup> IV once per week
 +
**Week 5 onwards: 4 mg/m<sup>2</sup> IV once every 2 weeks
 +
 
 +
'''Continued until achievement of CR or best response or for up to a total of 3 months (total of 14 doses of pentostatin)'''
  
 
===References===
 
===References===
 +
#'''MDACC 2004-0408:''' Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5. [https://ascopubs.org/doi/full/10.1200/JCO.2009.22.6688 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19805674 PubMed]
  
−
#Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11535503 PubMed]
+
=Relapsed or refractory, salvage therapy=
−
#Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21948296 PubMed]
+
==Bendamustine monotherapy {{#subobject:a1kc88|Regimen=1}}==
−
#Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. [https://ascopubs.org/doi/full/10.1200/JCO.2009.22.6688?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 PubMed]
+
{| class="wikitable" style="float:right; margin-left: 5px;"
−
 
+
|-
−
'''<u><big>Relapsed or refractory, salvage therapy</big></u>'''
+
|[[#top|back to top]]
−
 
+
|}
−
<big>'''<u>Alemtuzumab, Pentostatin</u>'''</big>
+
===Regimen {{#subobject:90ucj3a|Variant=1}}===
−
 
 
−
'''Regimen'''
 
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
! style="width: 25%" |Study
 
! style="width: 25%" |Study
 
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
 
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
−
!Efficacy
 
 
|-
 
|-
−
![https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 '''Ravandi et al. 2009''']
+
|[https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13175 Herbaux et al. 2014]
−
!'''Non-randomized'''
+
| style="background-color:#ffffbe" |Retrospective
−
!ORR: 69%, CR: 62%
+
|}
−
|}<br />
 
 
====Chemotherapy====
 
====Chemotherapy====
 +
* [[Bendamustine (Treanda)|Bendamustine]] 70 to 120 mg/m<sup>2</sup> IV once per day on days 1 & 2
  
−
*[[Alemtuzumab (Campath)]] First week: 3 mg IV on the first day,10 mg IV on the second day and 30 mg IV on the third day. Subsequent weeks: 30 mg IV three times weekly until achievement of CR or best response or for up to a total of 3 months
+
'''21-day cycle for 6 cycles'''
−
*[[Pentostatin (Nipent)]] 4 mg/m<sup>2</sup> IV weekly for 4 weeks then every 2 weeks until they achieved a CR or best response or for up to 10 more doses (total of 14 doses)
 
  
−
'''References'''
+
===References===
  
−
# Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. [https://ascopubs.org/doi/full/10.1200/JCO.2009.22.6688?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=19805674 PubMed]
+
# '''Retrospective:''' Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015 Mar;168(6):916-9. [https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13175 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25316212 PubMed]
  
−
'''<big><u>Bendamustine</u></big>'''
+
==Pentostatin & Alemtuzumab {{#subobject:a1kb018|Regimen=1}}==
−
 
+
{| class="wikitable" style="float:right; margin-left: 5px;"
−
Regimen
+
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:991cj3a|Variant=1}}===
 
{| class="wikitable" style="width: 50%; text-align:center;"  
 
{| class="wikitable" style="width: 50%; text-align:center;"  
−
! style="width: 25%" |Study
+
!style="width: 33%"|Study
−
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
−
!Herbaux et al. 2014
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ Ravandi et al. 2009 (MDACC 2004-0408)]
−
!Retrospective
+
| style="background-color:#91cf61" |Non-randomized
 +
|ORR: 69%, CR: 62%
 
|}
 
|}
 +
====Chemotherapy====
  
−
* [[Bendamustine (Treanda)|Bendamustine]] 70 to 120 mg/m<sup>2</sup> IV, days 1 and 2 every 3 weeks for total 6 cycles
+
*[[Alemtuzumab (Campath)]] as follows:
 +
**First week: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
 +
**Subsequent weeks: 30 mg IV three times weekly
 +
*[[Pentostatin (Nipent)]] as follows:
 +
**Weeks 1 to 4: 4 mg/m<sup>2</sup> IV once per week
 +
**Week 5 onwards: 4 mg/m<sup>2</sup> IV once every 2 weeks
  
−
'''References'''
+
'''Continued until achievement of CR or best response or for up to a total of 3 months (total of 14 doses of pentostatin)'''
  
−
# Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015 Mar;168(6):916-9.[https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13175 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=25316212 PubMed] <br />
+
===References===
 +
#'''MDACC 2004-0408:''' Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5. [https://ascopubs.org/doi/full/10.1200/JCO.2009.22.6688 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881363/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19805674 PubMed]
  
−
'''<big><u>Venetoclax, Ibrutinib</u></big>''' (ongoing clinical trial, [https://clinicaltrials.gov/ct2/show/NCT03873493 NCT03873493])
+
==Ibrutinib & Venetoclax {{#subobject:a1uh18|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:991ica|Variant=1}}===
 +
{| class="wikitable" style="width: 50%; text-align:center;"
 +
!style="width: 50%"|Study
 +
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://ashpublications.org/blood/article/134/Supplement_1/3965/424160/Combination-of-Venetoclax-and-Ibrutinib-Increases Kornauth et al. 2019]
 +
| style="background-color:#91cf61" |Non-randomized
 +
|-
 +
|}
 +
====Chemotherapy====
 +
* [[Ibrutinib (Imbruvica)|Ibrutinib]] 420 mg PO once per day
 +
* [[Venetoclax (Venclexta)|Venetoclax]] 400 to 600 mg PO once per day
  
−
Regimen
+
'''Continued indefinitely'''
  
−
* [[Venetoclax (Venclexta)|Venetoclax]] 400 mg, potentially up to 600 mg, orally once daily
+
===References===
−
* [[Ibrutinib (Imbruvica)|Ibrutinib]] 420 mg dosed orally once daily
 
−
 
 
−
'''References'''
 
  
−
# Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Poulain S, et al. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood. 2019;134(Supplement_1):3965.[https://ashpublications.org/blood/article/134/Supplement_1/3965/424160/Combination-of-Venetoclax-and-Ibrutinib-Increases?searchresult=1 link to original article]
+
# '''Abstract:''' Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Poulain S, et al. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood. 2019;134(Supplement_1):3965. [https://ashpublications.org/blood/article/134/Supplement_1/3965/424160/Combination-of-Venetoclax-and-Ibrutinib-Increases link to abstract]
  
−
'''<big><u>Consolidation therapy after upfront or salvage therapy</u></big>'''
+
=Consolidation therapy after upfront or salvage therapy=
  
 
'''[[Allogeneic HSCT]]''' evaluation suggested in eligible patients.  
 
'''[[Allogeneic HSCT]]''' evaluation suggested in eligible patients.  
  
−
'''<big>References</big>'''
+
===References===
−
 
+
# Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010 Jun;149(6):907-10. [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2010.08134.x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20201944 PubMed]
−
# Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010 Jun;149(6):907-10. [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2010.08134.x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=20201944 PubMed]
+
# Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz  MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7. [https://www.sciencedirect.com/science/article/pii/S1083879109005813 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/19961946 PubMed]
−
# Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz  MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7. [https://www.sciencedirect.com/science/article/pii/S1083879109005813?via%3Dihub link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=19961946 PubMed]
+
# '''Retrospective:''' Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond  V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012 May;26(5):972-6. [https://www.nature.com/articles/leu2011304 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22116553 PubMed]
−
# Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond  V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012 May;26(5):972-6.[https://www.nature.com/articles/leu2011304 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed?term=22116553 PubMed]
 
  
 
[[Category:T-cell prolymphocytic leukemia regimens]]
 
[[Category:T-cell prolymphocytic leukemia regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:T-cell leukemias]]
 
[[Category:T-cell leukemias]]

Revision as of 01:38, 8 January 2020

Section editor
Bdholaria.jpg
 Bhagirathbhai Dholaria, MBBS
Vanderbilt University
Nashville, TN
5 regimens on this page
5 variants on this page


Guidelines

NCCN

Diagnosis, staging and treatment response criteria (TPLL-ISG)

Upfront induction therapy

Alemtuzumab monotherapy

back to top

Regimen

Study Evidence Efficacy
Dearden et al. 2001 Non-randomized ORR: 76%, CR: 60%
Dearden et al. 2011 Non-randomized ORR: 91%, CR: 81%

Chemotherapy

  • Alemtuzumab (Campath) as follows:
    • First week: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
    • Subsequent weeks: 30 mg IV three times weekly

Continued until achievement of CR or best response or for up to a total of 3 months

References

  1. Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. link to original article PubMed
  2. Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. link to original article PubMed

Pentostatin & Alemtuzumab

back to top

Regimen

Study Evidence Efficacy
Ravandi et al. 2009 (MDACC 2004-0408) Non-randomized ORR: 69%, CR: 62%

Chemotherapy

  • Alemtuzumab (Campath) as follows:
    • First week: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
    • Subsequent weeks: 30 mg IV three times weekly
  • Pentostatin (Nipent) as follows:
    • Weeks 1 to 4: 4 mg/m2 IV once per week
    • Week 5 onwards: 4 mg/m2 IV once every 2 weeks

Continued until achievement of CR or best response or for up to a total of 3 months (total of 14 doses of pentostatin)

References

  1. MDACC 2004-0408: Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5. link to original article link to PMC article PubMed

Relapsed or refractory, salvage therapy

Bendamustine monotherapy

back to top

Regimen

Study Evidence
Herbaux et al. 2014 Retrospective

Chemotherapy

21-day cycle for 6 cycles

References

  1. Retrospective: Herbaux C, Genet P, Bouabdallah K, Pignon JM, Debarri H, Guidez S, Betrian S, Leleu X, Facon T, Morschhauser F, Damaj G, Cazin B, Ysebaert L. Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol. 2015 Mar;168(6):916-9. link to original article PubMed

Pentostatin & Alemtuzumab

back to top

Regimen

Study Evidence Efficacy
Ravandi et al. 2009 (MDACC 2004-0408) Non-randomized ORR: 69%, CR: 62%

Chemotherapy

  • Alemtuzumab (Campath) as follows:
    • First week: 3 mg IV once on day 1, then 10 mg IV once on day 2, then 30 mg IV once on day 3
    • Subsequent weeks: 30 mg IV three times weekly
  • Pentostatin (Nipent) as follows:
    • Weeks 1 to 4: 4 mg/m2 IV once per week
    • Week 5 onwards: 4 mg/m2 IV once every 2 weeks

Continued until achievement of CR or best response or for up to a total of 3 months (total of 14 doses of pentostatin)

References

  1. MDACC 2004-0408: Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5. link to original article link to PMC article PubMed

Ibrutinib & Venetoclax

back to top

Regimen

Study Evidence
Kornauth et al. 2019 Non-randomized

Chemotherapy

Continued indefinitely

References

  1. Abstract: Kornauth C, Herbaux C, Boidol B, Guillemette C, Caron P, Poulain S, et al. Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood. 2019;134(Supplement_1):3965. link to abstract

Consolidation therapy after upfront or salvage therapy

Allogeneic HSCT evaluation suggested in eligible patients.

References

  1. Krishnan B, Else M, Tjonnfjord GE, Cazin B, Carney D, Carter J, Ketterer N, Catovsky D, Ethell M, Matutes E, Dearden CE. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010 Jun;149(6):907-10. link to original article PubMed
  2. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7. link to SD article PubMed
  3. Retrospective: Wiktor-Jedrzejczak W, Dearden C, de Wreede L, van Biezen A, Brinch L, Leblond V, Brune M, Volin L, Kazmi M, Nagler A, Schetelig J, de Witte T, Dreger P; EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia. 2012 May;26(5):972-6. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=T-cell_prolymphocytic_leukemia&oldid=41746"